Int. J. Mol. Sci. 2013, 14(12), 24603-24618; doi:10.3390/ijms141224603
Article

The Antidiabetic Drug Metformin Inhibits the Proliferation of Bladder Cancer Cells in Vitro and in Vivo

1 Minimally Invasive Urology Center, Provincial Hospital Affiliated to Shandong University, Jinan 250021, China 2 Department of Urology, the First Hospital of Xi'an Jiaotong University, Xi'an 710061, China 3 Oncology Research Laboratory, Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an Jiaotong University, Xi'an 710061, China
* Authors to whom correspondence should be addressed.
Received: 28 October 2013; in revised form: 21 November 2013 / Accepted: 4 December 2013 / Published: 18 December 2013
(This article belongs to the Special Issue Molecular Bases of Cancer Research)
PDF Full-text Download PDF Full-Text [2503 KB, uploaded 18 December 2013 09:36 CET]
Abstract: Recent studies suggest that metformin, a widely used antidiabetic agent, may reduce cancer risk and improve prognosis of certain malignancies. However, the mechanisms for the anti-cancer effects of metformin remain uncertain. In this study, we investigated the effects of metformin on human bladder cancer cells and the underlying mechanisms. Metformin significantly inhibited the proliferation and colony formation of 5637 and T24 cells in vitro; specifically, metformin induced an apparent cell cycle arrest in G0/G1 phases, accompanied by a strong decrease of cyclin D1, cyclin-dependent kinase 4 (CDK4), E2F1 and an increase of p21waf-1. Further experiments revealed that metformin activated AMP-activated protein kinase (AMPK) and suppressed mammalian target of rapamycin (mTOR), the central regulator of protein synthesis and cell growth. Moreover, daily treatment of metformin led to a substantial inhibition of tumor growth in a xenograft model with concomitant decrease in the expression of proliferating cell nuclear antigen (PCNA), cyclin D1 and p-mTOR. The in vitro and in vivo results demonstrate that metformin efficiently suppresses the proliferation of bladder cancer cells and suggest that metformin may be a potential therapeutic agent for the treatment of bladder cancer.
Keywords: metformin; bladder cancer; cyclin D1; AMPK; mTOR

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Zhang, T.; Guo, P.; Zhang, Y.; Xiong, H.; Yu, X.; Xu, S.; Wang, X.; He, D.; Jin, X. The Antidiabetic Drug Metformin Inhibits the Proliferation of Bladder Cancer Cells in Vitro and in Vivo. Int. J. Mol. Sci. 2013, 14, 24603-24618.

AMA Style

Zhang T, Guo P, Zhang Y, Xiong H, Yu X, Xu S, Wang X, He D, Jin X. The Antidiabetic Drug Metformin Inhibits the Proliferation of Bladder Cancer Cells in Vitro and in Vivo. International Journal of Molecular Sciences. 2013; 14(12):24603-24618.

Chicago/Turabian Style

Zhang, Tao; Guo, Peng; Zhang, Yinan; Xiong, Hui; Yu, Xiao; Xu, Shan; Wang, Xinyang; He, Dalin; Jin, Xunbo. 2013. "The Antidiabetic Drug Metformin Inhibits the Proliferation of Bladder Cancer Cells in Vitro and in Vivo." Int. J. Mol. Sci. 14, no. 12: 24603-24618.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert